Unique ID issued by UMIN | UMIN000014395 |
---|---|
Receipt number | R000016636 |
Scientific Title | An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis |
Date of disclosure of the study information | 2014/07/01 |
Last modified on | 2022/07/04 18:13:41 |
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosis
Japan |
Hepatitis C virus-induced cirrhosis
Hepato-biliary-pancreatic medicine |
Others
NO
To investigate safety and tolerability of PRI-724 in patients with HCV-induced cirrhosis
Safety
Phase I
Adverse events and adverse drug reactions (including subjective symptoms and abnormal laboratory values)
(1)Child-Pugh Score
(2)Liver biopsy: Histology Activity Index (HAI)
(3)Serum albumin level
(4)Serum fibrosis marker level(s)
(5)Ascitic fluid level
(6)Improvement rate of lower leg edema
(7)Pharmacokinetics
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Continuous intravenous administration for a week continuous intravenous administration of PRI-724
20 | years-old | <= |
75 | years-old | > |
Male and Female
(1) Presence of cirrhosis due to hepatitis C virus.
1) Serum HCV-RNA test positive
2) Definitive diagnosis of cirrhosis established by liver biopsy (HAI score: Grade IV-D).
(2)Child-Pugh Class A or B at the time of informed consent, with no likelihood of improvement with existing medical treatment.
(3)Performance Status: 0 - 2.
(4)Between =>20 and <75 years of age at the time of providing written consent.
(5)Having provided voluntary written consent for participation in this study.
(6)Esophageal and gastric varices are well controlled
(1)Patients with cirrhosis due to causes other than hepatitis C virus; or patients with cirrhosis due to unknown causes.
(2)Patients with a history of primary liver cancer or a complication thereof.
(3)Patients with a complication of malignant tumor or a history thereof (within 5 years prior to screening).
(4)Patients in whom such active viral infections as HBV, HIV or ATCL or syphilis infection cannot be ruled out.
(5)Patients with serum creatinine >1.5 times over upper normal or creatinine clearance =<60 mL/min/1.73 m2.
(6)Patients with hemoglobin <8 g/dL.
(7)Patients with platelet count <50,000 /µL.
(8)Patients with T.Bil =>3.0 mg/dL.
(9)Patients with a complication of poorly controlled diabetes, hypertension or heart failure.
(10)Patients with a complication of mental disorder requiring treatment.
(11)Patients with serious allergy to contrast media or a history thereof.
(12)Patients with allergy to inactive ingredients of the study drug.
(13)Patients who have received interferon, ribavirin or anti-HCV agents within 12 weeks before registration in this study.
(14)When the medical treatment to a primary disease is carried out, Patient who was changed the dosage and administration within the 12 weeks before registration.
(15)Patients with a history of drug or alcohol addiction within five years at the time of providing written consent or a history of drug or alcohol abuse within the past one year.
(16)The patient who received a liver transplant or other organ transplants (a bone marrow transplantation is included), and the patient for whom intravenous administration and venous access are difficult.
(17)Patients contraindicated for liver biopsy.
(18)Female patients who are pregnant or suspected to be pregnant; or those who desire to get pregnant during the study period or those of childbearing potential.
(19)Male patients who do not consent to practice birth control during the clinical study.
18
1st name | Kiminori |
Middle name | |
Last name | Kiminori Kimura |
Tokyo metropolitan Komagome Hospital
Division of Hepatology
113-8677
3-18-22,Honkomagome ,Bunkyo-ku,Tokyo
03-3823-2101
kiminori_kimura@tmhp.jp
1st name | Kiminori |
Middle name | |
Last name | Kimura |
Tokyo metropolitan Komagome Hospital
Division of Hepatology
113-8677
3-18-22,Honkomagome ,Bunkyo-ku,Tokyo
03-3823-2101
kiminori_kimura@tmhp.jp
Tokyo metropolitan Komagome Hospital
Japan Agency for Medical Research and Development (AMED)
Japanese Governmental office
PRISM Pharma Co.,Ltd.
Komagome Hospital Institutional Review Board
3-18-22,Honkomagome ,Bunkyo-ku,Tokyo,Japan
03-3823-2101
km_koma_chiken@tmhp.jp
YES
NCT02195440
ClinicalTrials.gov
20-0458
東京都立駒込病院(東京都)
2014 | Year | 07 | Month | 01 | Day |
Published
16
Main results already published
2014 | Year | 06 | Month | 09 | Day |
2014 | Year | 04 | Month | 18 | Day |
2014 | Year | 07 | Month | 16 | Day |
2016 | Year | 08 | Month | 08 | Day |
2016 | Year | 12 | Month | 12 | Day |
2017 | Year | 01 | Month | 31 | Day |
2014 | Year | 06 | Month | 27 | Day |
2022 | Year | 07 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016636
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |